Biostem Technologies Inc
OTC:BSEM

Watchlist Manager
Biostem Technologies Inc Logo
Biostem Technologies Inc
OTC:BSEM
Watchlist
Price: 4.29 USD 8.88% Market Closed
Market Cap: 71.8m USD

Biostem Technologies Inc
Net Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biostem Technologies Inc
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Biostem Technologies Inc
OTC:BSEM
Net Income
-$7.9m
CAGR 3-Years
-49%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Income
$25.1B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Net Income
$6B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Net Income
$9.9B
CAGR 3-Years
-31%
CAGR 5-Years
3%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Net Income
$19B
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Net Income
$18.4B
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
23%
No Stocks Found

Biostem Technologies Inc
Glance View

Market Cap
71.8m USD
Industry
Pharmaceuticals

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.

BSEM Intrinsic Value
Not Available

See Also

What is Biostem Technologies Inc's Net Income?
Net Income
-7.9m USD

Based on the financial report for Dec 31, 2024, Biostem Technologies Inc's Net Income amounts to -7.9m USD.

What is Biostem Technologies Inc's Net Income growth rate?
Net Income CAGR 3Y
-49%

Over the last year, the Net Income growth was 0%. The average annual Net Income growth rates for Biostem Technologies Inc have been -49% over the past three years .

Back to Top